Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

AMG 423

Other · developed by Cytokinetics

Phase 1 Most advanced trial (none active)
CYTK Developer
1 Registered trials

What is AMG 423?

AMG 423 is an investigational drug studied in Heart Failure.

At a glance

Drug type
Other
Therapy area
Cardiovascular
Developer
Cytokinetics (CYTK)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT01737866 Phase 1 Heart Failure Completed CYTK

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Heart Failure

More from Cytokinetics

Aficamten FDA approved CK-3828136 Phase 1 Omecamtiv Mecarbil Phase 3 Reldesemtiv Phase 3 SB-743921 Phase 1/2 Tirasemtiv Phase 3 Ulacamten Phase 2

Follow CYTK, the company behind AMG 423

See CYTK's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

CYTK catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.